RNS & Investor News

2024

Notice of Results

23 March 2016

Analyst Briefing

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its preliminary results for the year ended 30 November 2015 on Thursday 14 April 2016.

A briefing for analysts will take place in the Gresham room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW at 9.30am on Thursday 14 April 2016.

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP (Joint Broker)
Claire Louise Noyce
Tel: 020 3764 2341
Peterhouse Corporate Finance Ltd (Joint Broker)
Duncan Vasey / Lucy Williams
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

2023

Notice of Results

23 March 2016

Analyst Briefing

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its preliminary results for the year ended 30 November 2015 on Thursday 14 April 2016.

A briefing for analysts will take place in the Gresham room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW at 9.30am on Thursday 14 April 2016.

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP (Joint Broker)
Claire Louise Noyce
Tel: 020 3764 2341
Peterhouse Corporate Finance Ltd (Joint Broker)
Duncan Vasey / Lucy Williams
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

2022

Notice of Results

23 March 2016

Analyst Briefing

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its preliminary results for the year ended 30 November 2015 on Thursday 14 April 2016.

A briefing for analysts will take place in the Gresham room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW at 9.30am on Thursday 14 April 2016.

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP (Joint Broker)
Claire Louise Noyce
Tel: 020 3764 2341
Peterhouse Corporate Finance Ltd (Joint Broker)
Duncan Vasey / Lucy Williams
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

2021

Notice of Results

23 March 2016

Analyst Briefing

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its preliminary results for the year ended 30 November 2015 on Thursday 14 April 2016.

A briefing for analysts will take place in the Gresham room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW at 9.30am on Thursday 14 April 2016.

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP (Joint Broker)
Claire Louise Noyce
Tel: 020 3764 2341
Peterhouse Corporate Finance Ltd (Joint Broker)
Duncan Vasey / Lucy Williams
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

2020

Notice of Results

23 March 2016

Analyst Briefing

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its preliminary results for the year ended 30 November 2015 on Thursday 14 April 2016.

A briefing for analysts will take place in the Gresham room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW at 9.30am on Thursday 14 April 2016.

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP (Joint Broker)
Claire Louise Noyce
Tel: 020 3764 2341
Peterhouse Corporate Finance Ltd (Joint Broker)
Duncan Vasey / Lucy Williams
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

2019

Notice of Results

23 March 2016

Analyst Briefing

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its preliminary results for the year ended 30 November 2015 on Thursday 14 April 2016.

A briefing for analysts will take place in the Gresham room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW at 9.30am on Thursday 14 April 2016.

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP (Joint Broker)
Claire Louise Noyce
Tel: 020 3764 2341
Peterhouse Corporate Finance Ltd (Joint Broker)
Duncan Vasey / Lucy Williams
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

2018

Notice of Results

23 March 2016

Analyst Briefing

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its preliminary results for the year ended 30 November 2015 on Thursday 14 April 2016.

A briefing for analysts will take place in the Gresham room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW at 9.30am on Thursday 14 April 2016.

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP (Joint Broker)
Claire Louise Noyce
Tel: 020 3764 2341
Peterhouse Corporate Finance Ltd (Joint Broker)
Duncan Vasey / Lucy Williams
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

2017

Notice of Results

23 March 2016

Analyst Briefing

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its preliminary results for the year ended 30 November 2015 on Thursday 14 April 2016.

A briefing for analysts will take place in the Gresham room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW at 9.30am on Thursday 14 April 2016.

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP (Joint Broker)
Claire Louise Noyce
Tel: 020 3764 2341
Peterhouse Corporate Finance Ltd (Joint Broker)
Duncan Vasey / Lucy Williams
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

2016

Notice of Results

23 March 2016

Analyst Briefing

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its preliminary results for the year ended 30 November 2015 on Thursday 14 April 2016.

A briefing for analysts will take place in the Gresham room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW at 9.30am on Thursday 14 April 2016.

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP (Joint Broker)
Claire Louise Noyce
Tel: 020 3764 2341
Peterhouse Corporate Finance Ltd (Joint Broker)
Duncan Vasey / Lucy Williams
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

2015

Notice of Results

23 March 2016

Analyst Briefing

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its preliminary results for the year ended 30 November 2015 on Thursday 14 April 2016.

A briefing for analysts will take place in the Gresham room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW at 9.30am on Thursday 14 April 2016.

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP (Joint Broker)
Claire Louise Noyce
Tel: 020 3764 2341
Peterhouse Corporate Finance Ltd (Joint Broker)
Duncan Vasey / Lucy Williams
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

2014

Notice of Results

23 March 2016

Analyst Briefing

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its preliminary results for the year ended 30 November 2015 on Thursday 14 April 2016.

A briefing for analysts will take place in the Gresham room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW at 9.30am on Thursday 14 April 2016.

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP (Joint Broker)
Claire Louise Noyce
Tel: 020 3764 2341
Peterhouse Corporate Finance Ltd (Joint Broker)
Duncan Vasey / Lucy Williams
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

2013

Notice of Results

23 March 2016

Analyst Briefing

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its preliminary results for the year ended 30 November 2015 on Thursday 14 April 2016.

A briefing for analysts will take place in the Gresham room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW at 9.30am on Thursday 14 April 2016.

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP (Joint Broker)
Claire Louise Noyce
Tel: 020 3764 2341
Peterhouse Corporate Finance Ltd (Joint Broker)
Duncan Vasey / Lucy Williams
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002